Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin + Metformin in T2DM Inadequately Controlled on Metformin
NCT00121667Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2005
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of saxagliptin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by AstraZeneca. Primary endpoint: Change From Baseline in Hemoglobin A1c at 24 weeks. Started Aug 2005; status: completed.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00121667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121667.